Recent drug-repurposing-driven advances in the discovery of novel antibiotics

Ananda Kumar Konreddy, Grandhe Usha Rani, Kyeong Lee, Yongseok Choi

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Drug repurposing is a safe and successful pathway to speed up the novel drug discovery and development processes compared with de novo drug discovery approaches. Drug repurposing uses FDA-approved drugs and drugs that failed in clinical trials, which have detailed information on potential toxicity, formulation, and pharmacology. Technical advancements in the informatics, genomics, and biological sciences account for the major success of drug repurposing in identifying secondary indications of existing drugs. Drug repurposing is playing a vital role in filling the gap in the discovery of potential antibiotics. Bacterial infections emerged as an ever-increasing global public health threat by dint of multidrug resistance to existing drugs. This raises the urgent need of development of new antibiotics that can effectively fight multidrug-resistant bacterial infections (MDRBIs). The present review describes the key role of drug repurposing in the development of antibiotics during 2016–2017 and of the details of recently FDA-approved antibiotics, pipeline antibiotics, and antibacterial properties of various FDA-approved drugs of anti-cancer, anti-fungal, anti-hyperlipidemia, antiinflammatory, anti-malarial, anti-parasitic, anti-viral, genetic disorder, immune modulator, etc. Further, in view of combination therapies with the existing antibiotics, their potential for new implications for MDRBIs is discussed. The current review may provide essential data for the development of quick, safe, effective, and novel antibiotics for current needs and suggest acuity in its effective implications for inhibiting MDRBIs by repurposing existing drugs.

Original languageEnglish
Pages (from-to)5363-5388
Number of pages26
JournalCurrent Medicinal Chemistry
Volume26
Issue number28
DOIs
Publication statusPublished - 2019 Jan 1

Keywords

  • Anti-bacterial activity
  • Antibiotics
  • Bacterial infections
  • Drug discovery
  • Drug repurposing
  • FDA-approved drugs

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Recent drug-repurposing-driven advances in the discovery of novel antibiotics. / Konreddy, Ananda Kumar; Rani, Grandhe Usha; Lee, Kyeong; Choi, Yongseok.

In: Current Medicinal Chemistry, Vol. 26, No. 28, 01.01.2019, p. 5363-5388.

Research output: Contribution to journalReview article

Konreddy, Ananda Kumar ; Rani, Grandhe Usha ; Lee, Kyeong ; Choi, Yongseok. / Recent drug-repurposing-driven advances in the discovery of novel antibiotics. In: Current Medicinal Chemistry. 2019 ; Vol. 26, No. 28. pp. 5363-5388.
@article{97c5221e09cc42919589de9abfae46ac,
title = "Recent drug-repurposing-driven advances in the discovery of novel antibiotics",
abstract = "Drug repurposing is a safe and successful pathway to speed up the novel drug discovery and development processes compared with de novo drug discovery approaches. Drug repurposing uses FDA-approved drugs and drugs that failed in clinical trials, which have detailed information on potential toxicity, formulation, and pharmacology. Technical advancements in the informatics, genomics, and biological sciences account for the major success of drug repurposing in identifying secondary indications of existing drugs. Drug repurposing is playing a vital role in filling the gap in the discovery of potential antibiotics. Bacterial infections emerged as an ever-increasing global public health threat by dint of multidrug resistance to existing drugs. This raises the urgent need of development of new antibiotics that can effectively fight multidrug-resistant bacterial infections (MDRBIs). The present review describes the key role of drug repurposing in the development of antibiotics during 2016–2017 and of the details of recently FDA-approved antibiotics, pipeline antibiotics, and antibacterial properties of various FDA-approved drugs of anti-cancer, anti-fungal, anti-hyperlipidemia, antiinflammatory, anti-malarial, anti-parasitic, anti-viral, genetic disorder, immune modulator, etc. Further, in view of combination therapies with the existing antibiotics, their potential for new implications for MDRBIs is discussed. The current review may provide essential data for the development of quick, safe, effective, and novel antibiotics for current needs and suggest acuity in its effective implications for inhibiting MDRBIs by repurposing existing drugs.",
keywords = "Anti-bacterial activity, Antibiotics, Bacterial infections, Drug discovery, Drug repurposing, FDA-approved drugs",
author = "Konreddy, {Ananda Kumar} and Rani, {Grandhe Usha} and Kyeong Lee and Yongseok Choi",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/0929867325666180706101404",
language = "English",
volume = "26",
pages = "5363--5388",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "28",

}

TY - JOUR

T1 - Recent drug-repurposing-driven advances in the discovery of novel antibiotics

AU - Konreddy, Ananda Kumar

AU - Rani, Grandhe Usha

AU - Lee, Kyeong

AU - Choi, Yongseok

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Drug repurposing is a safe and successful pathway to speed up the novel drug discovery and development processes compared with de novo drug discovery approaches. Drug repurposing uses FDA-approved drugs and drugs that failed in clinical trials, which have detailed information on potential toxicity, formulation, and pharmacology. Technical advancements in the informatics, genomics, and biological sciences account for the major success of drug repurposing in identifying secondary indications of existing drugs. Drug repurposing is playing a vital role in filling the gap in the discovery of potential antibiotics. Bacterial infections emerged as an ever-increasing global public health threat by dint of multidrug resistance to existing drugs. This raises the urgent need of development of new antibiotics that can effectively fight multidrug-resistant bacterial infections (MDRBIs). The present review describes the key role of drug repurposing in the development of antibiotics during 2016–2017 and of the details of recently FDA-approved antibiotics, pipeline antibiotics, and antibacterial properties of various FDA-approved drugs of anti-cancer, anti-fungal, anti-hyperlipidemia, antiinflammatory, anti-malarial, anti-parasitic, anti-viral, genetic disorder, immune modulator, etc. Further, in view of combination therapies with the existing antibiotics, their potential for new implications for MDRBIs is discussed. The current review may provide essential data for the development of quick, safe, effective, and novel antibiotics for current needs and suggest acuity in its effective implications for inhibiting MDRBIs by repurposing existing drugs.

AB - Drug repurposing is a safe and successful pathway to speed up the novel drug discovery and development processes compared with de novo drug discovery approaches. Drug repurposing uses FDA-approved drugs and drugs that failed in clinical trials, which have detailed information on potential toxicity, formulation, and pharmacology. Technical advancements in the informatics, genomics, and biological sciences account for the major success of drug repurposing in identifying secondary indications of existing drugs. Drug repurposing is playing a vital role in filling the gap in the discovery of potential antibiotics. Bacterial infections emerged as an ever-increasing global public health threat by dint of multidrug resistance to existing drugs. This raises the urgent need of development of new antibiotics that can effectively fight multidrug-resistant bacterial infections (MDRBIs). The present review describes the key role of drug repurposing in the development of antibiotics during 2016–2017 and of the details of recently FDA-approved antibiotics, pipeline antibiotics, and antibacterial properties of various FDA-approved drugs of anti-cancer, anti-fungal, anti-hyperlipidemia, antiinflammatory, anti-malarial, anti-parasitic, anti-viral, genetic disorder, immune modulator, etc. Further, in view of combination therapies with the existing antibiotics, their potential for new implications for MDRBIs is discussed. The current review may provide essential data for the development of quick, safe, effective, and novel antibiotics for current needs and suggest acuity in its effective implications for inhibiting MDRBIs by repurposing existing drugs.

KW - Anti-bacterial activity

KW - Antibiotics

KW - Bacterial infections

KW - Drug discovery

KW - Drug repurposing

KW - FDA-approved drugs

UR - http://www.scopus.com/inward/record.url?scp=85070630521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070630521&partnerID=8YFLogxK

U2 - 10.2174/0929867325666180706101404

DO - 10.2174/0929867325666180706101404

M3 - Review article

C2 - 29984648

AN - SCOPUS:85070630521

VL - 26

SP - 5363

EP - 5388

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 28

ER -